Search Results for:
September 2022
Three clinical sites open, patient website established from Netherton Syndrome study
August 2022
$16.8 million oversubscribed and upsized public offering
July 2022
Scientific Advice received from EMA
July 2022
Commercialization agreement signed for Canadian market
July 2022
First site opened for Netherton Syndrome clinical study
June 2022
Distribution agreement covering Greater China
May 2022
Second exclusive research agreement with QUT for scleroderma treatment
April 2022
FDA clearance of IND for QRX003 for Netherton Syndrome
March 2022
Submits Investigational New Drug application to FDA and Scientific Advice Briefing document to EMA